Mr Donal O'Dwyer,
Mr Donal O’Dwyer is an innovative, growth-driven top management executive and corporate officer with over 25 years of worldwide experience in medical devices in sales and marketing, product development and manufacturing operations. From 1996 to 2003, Mr O’Dwyer worked for Cordis Cardiology, the cardiology division of Johnson & Johnson’s Cordis Corporation, initially as its president, Europe, and from 2000 as its worldwide president. Prior to joining Cordis, he worked with Baxter Healthcare, now Edwards Lifesciences, rising from plant manager in Ireland to president of the Cardiovascular Group, Europe. He is a qualified civil engineer with an MBA. Mr O’Dwyer is on the Board of Directors of a number of life science companies including Cochlear, Mesoblast, Fisher & Paykel Healthcare and NIB Health Funds.
Mr Ashish Mitra, Founder, CEO & Chief Technology Officer
Mr Ashish Mitra has completed his post graduate training in mechanical engineering at Stanford University, with specialization in medical devices, product design and design for manufacturability. Passionate about medical device engineering he has developed technical expertise in the field of treating aortic, cardiac and peripheral vascular disease at the R&D Groups of Medtronic Vascular and Medtronic Structural Heart. His experience spans the full spectrum of medical technology development from conception to successful regulatory approvals. A creative inventor with an expanding IP portfolio, he has received several recognitions including awards from the J.F. Lincoln Foundation, USA and the Indian National Academy of Engineers, India. He has honorary appointments at the University of Sydney and the Heart Research Institute, Sydney, Australia.
Dr Martin Ng, Founder & Chief Medical Officer
Dr Martin Ng, MD PhD, is an interventional cardiologist who has completed his fellowship training at Stanford University Medical Centre. Originally from Australia, he graduated with first class honours in medicine from the University of Sydney prior to completing a PhD on the molecular biology of early coronary artery disease. His research has garnered numerous awards and honours including the Royal Australasian College of Physicians' Young Investigator of the Year in 2001 and selection to the American Heart Association Late Breaking Basic Sciences Sessions for innovative, important and novel science in 2002. Dr Ng's core long term interests are focussed on bench-to-bedside innovation within interventional cardiology, including therapeutic angiogenesis and novel cardiovascular device related treatments for atherosclerosis.